(Q41823201)

12 October 2017

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. (English)

1 reference

12 October 2017

1 reference

ChEBI release 2020-05-28

1 reference

Robert Provenzano

1

1 reference

12 October 2017

Anatole Besarab

2

1 reference

12 October 2017

Chao H Sun

3

1 reference

12 October 2017

Susan A Diamond

4

1 reference

12 October 2017

John H Durham

5

1 reference

12 October 2017

Jose L Cangiano

6

1 reference

12 October 2017

Joseph R Aiello

7

1 reference

12 October 2017

James E Novak

8

1 reference

12 October 2017

Tyson Lee

9

1 reference

12 October 2017

Robert Leong

10

1 reference

12 October 2017

Brian K Roberts

11

1 reference

12 October 2017

Khalil G Saikali

12

1 reference

12 October 2017

Stefan Hemmerich

13

1 reference

12 October 2017

Lynda A Szczech

14

1 reference

12 October 2017

Kin-Hung Peony Yu

15

1 reference

12 October 2017

Thomas B Neff

16

1 reference

12 October 2017

19 April 2016

1 reference

Clinical Journal of the American Society of Nephrology

12 October 2017

1 reference

12 October 2017

11

1 reference

12 October 2017

6

1 reference

12 October 2017

982-991

1 reference

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Effect of red cell transfusions on future kidney transplantation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Prevalence of chronic kidney disease in the United States

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

The treatment of anemia in chronic kidney disease: understandings in 2006.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Recent advances in erythropoietic agents in renal anemia

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Hyporesponsiveness to erythropoietic therapy due to chronic inflammation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

A rationale for an individualized haemoglobin target

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

A randomized controlled study of iron supplementation in patients treated with erythropoietin

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Trends in anemia treatment with erythropoietin usage and patient outcomes.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (4800 m)

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4891748

CKD stage at nephrology referral and factors influencing the risks of ESRD and death

2 December 2018

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

1 reference

12 December 2020

The effects of recombinant human erythropoietin on mean corpuscular volume in patients with the anemia of chronic renal failure

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.06890615

1 reference

12 October 2017

1 reference

12 October 2017

PubMed publication ID

27094610

1 reference